Oncolytic virotherapy reaches adolescence - PubMed

Affiliations

• PMID: 20734404
• DOI: 10.1002/pbc.22724

Review

Oncolytic virotherapy reaches adolescence

Adrienne M Hammill et al. Pediatr Blood Cancer. 2010.

Abstract

Lytic viruses kill cells as a consequence of their normal replication life cycle. The idea of harnessing viruses to kill cancer cells arose over a century ago, before viruses were even discovered, from medical case reports of infections associated with cancer remissions. Since then, there has been no shortage of hype, hope, or fear regarding the prospect of oncolytic virotherapy for cancer. Early developments in the field included encouraging antitumor efficacy both in animal studies in the 1920s-1940s and in human clinical trials in the 1950s-1970s. Despite its long-standing history, oncolytic virotherapy was an idea ahead of its time. Without needed advances in molecular biology, virology, immunology, and clinical research ethics, early clinical trials resulted in infectious complications and were fraught with controversial research conduct, so that enthusiasm in the medical community waned. Oncolytic virotherapy is now experiencing a major growth spurt, having sustained numerous laboratory advances and undergone multiple encouraging adult clinical trials, and is now witnessing the emergence of pediatric trials. Here we review the history and salient biology of the field, including preclinical and clinical data, with a special emphasis on those agents now being tested in pediatric cancer patients.

Similar articles

• Oncolytic virotherapy of breast cancer.

  Hartkopf AD, Fehm T, Wallwiener D, Lauer UM. Hartkopf AD, et al. Gynecol Oncol. 2011 Oct;123(1):164-71. doi: 10.1016/j.ygyno.2011.06.021. Epub 2011 Jul 20. Gynecol Oncol. 2011. PMID: 21764108 Review.

• Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.

  Sinkovics JG, Horvath JC. Sinkovics JG, et al. Arch Immunol Ther Exp (Warsz). 2008 Dec;56 Suppl 1:3s-59s. doi: 10.1007/s00005-008-0047-9. Epub 2008 Dec 23. Arch Immunol Ther Exp (Warsz). 2008. PMID: 19104757 Review.

• Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

  Liu TC, Galanis E, Kirn D. Liu TC, et al. Nat Clin Pract Oncol. 2007 Feb;4(2):101-17. doi: 10.1038/ncponc0736. Nat Clin Pract Oncol. 2007. PMID: 17259931 Review.

• Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.

  Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. Zemp FJ, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):103-17. doi: 10.1016/j.cytogfr.2010.04.001. Epub 2010 May 18. Cytokine Growth Factor Rev. 2010. PMID: 20483653 Review.

• Recent progress in the battle between oncolytic viruses and tumours.

  Parato KA, Senger D, Forsyth PA, Bell JC. Parato KA, et al. Nat Rev Cancer. 2005 Dec;5(12):965-76. doi: 10.1038/nrc1750. Nat Rev Cancer. 2005. PMID: 16294217 Review.

Cited by

• VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.

  Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP. Currier MA, et al. Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12. Mol Ther. 2013. PMID: 23481323 Free PMC article.

• Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.

  Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, Eubank TD, Goins WF, Glorioso JC, Cohen JB, Grandi P, Hildeman DA, Cripe TP. Leddon JL, et al. Mol Ther Oncolytics. 2015 Jan 21;1:14010. doi: 10.1038/mto.2014.10. eCollection 2015. Mol Ther Oncolytics. 2015. PMID: 27119100 Free PMC article.

• Applications of coxsackievirus A21 in oncology.

  Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. Bradley S, et al. Oncolytic Virother. 2014 Apr 10;3:47-55. doi: 10.2147/OV.S56322. eCollection 2014. Oncolytic Virother. 2014. PMID: 27512662 Free PMC article. Review.

• Cytotoxic effect of a combination of bluetongue virus and radiation on prostate cancer.

  Wang W, Chen MN, Cheng K, Zhan LL, Zhang J. Wang W, et al. Exp Ther Med. 2014 Aug;8(2):635-641. doi: 10.3892/etm.2014.1751. Epub 2014 Jun 2. Exp Ther Med. 2014. PMID: 25009632 Free PMC article.

• Analysis of a Multiple Delays Model for Treatment of Cancer with Oncolytic Virotherapy.

  El Alami Laaroussi A, Hia ME, Rachik M, Ghazzali R. El Alami Laaroussi A, et al. Comput Math Methods Med. 2019 Sep 30;2019:1732815. doi: 10.1155/2019/1732815. eCollection 2019. Comput Math Methods Med. 2019. PMID: 31662784 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database